TETeresa Elo

Teresa Elo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Teresa Elo has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Eeva Valve

    Departments of Cell Biology and AnatomyPharmacologyDrug Development and TherapeuticsTurku Center for Disease ModelingInstitute of Biomedicine, University of Turku, Kiinamyllynkatu 10, 20520 Turku, FinlandFunctional Foods ForumUniversity of Turku, Turku, FinlandDepartment of Laboratory MedicineMAS University Hospital, Lund University, Malmö, Sweden

    2 shared publications
  • Lan Yu

    Departments of Cell Biology and AnatomyPharmacologyDrug Development and TherapeuticsTurku Center for Disease ModelingInstitute of Biomedicine, University of Turku, Kiinamyllynkatu 10, 20520 Turku, FinlandFunctional Foods ForumUniversity of Turku, Turku, FinlandDepartment of Laboratory MedicineMAS University Hospital, Lund University, Malmö, Sweden

    2 shared publications
  • Pirkko Härkönen

    2 shared publications
  • Eeva M. Valve

    Department of Anatomy and MediCity Research Laboratory, Institute of Biomedicine, University of Turku, Turku, Finland

    1 shared publication
  • Jorma Toppari

    Department of Cell Biology and Anatomy, Institute of Biomedicine, University of Turku, Turku, Finland

    1 shared publication
  • Matti Poutanen

    Department of Cell Biology and Anatomy, Institute of Biomedicine, University of Turku, Turku, Finland

    1 shared publication

Latest Publications

  • Deficiency of ERβ and prostate tumorigenesis in FGF8b transgenic mice

    by Teresa Elo, Lan Yu, Eeva Valve, Sari Mäkelä, Pirkko Härkönen

    Estrogens contribute to the development and growth of the prostate and are implicated in prostate tumorigenesis. In their target tissues, estrogens mediate their effects via estrogen receptor α (ERα (ESR1)) and β (ERβ (ESR2)). Hyperplasia and decreased differentiation of epithelial cells in the prostate have been reported inERβknockout (BERKO) mice. Herein, we studied the effect of ERβ deficiency on prostate tumorigenesis by crossing BERKOFVBmice with prostate-targeted human fibroblast growth factor 8b transgenic (FGF8b-Tg) mice. Consistent with results described in our previous report, the prostates of 1-year-oldFGF8b-Tg mice displayed stromal aberrations, prostatic intraepithelial neoplasia (mPIN) lesions, inflammation, and occasionally cancer. The prostates of BERKOFVBmice exhibited mild epithelial hypercellularity and inflammation. The prostate phenotypes ofFGF8b-Tg-BERKOFVBmice closely resembled those ofFGF8b-Tg mice. However, mucinous metaplasia, indicated by Goblet-like cells in the epithelium, was significantly more frequent in the prostates ofFGF8b-Tg-BERKOFVBmice when compared withFGF8b-Tg mice. Furthermore, compared withFGF8b-Tg mice, there was a tendency for increased frequency of inflammation but milder hyperplasias in the prostate stroma ofFGF8b-Tg-BERKOFVBmice. The expression levels of mRNAs forFGF8b-regulated genes including osteopontin (Spp1), connective tissue growth factor (Ctgf), fibroblast growth factor receptors (Fgfrs), and steroid hormone receptors and cytokines were similar in the prostates ofFGF8b-Tg andFGF8b-Tg-BERKOFVBmice. Our results indicate that ERβ plays a role in the differentiation of the prostatic epithelium and, potentially, in the defensive mechanism required for protection against inflammation but do not support a direct tumor-suppressive function of ERβ in the prostate ofFGF8b-Tg mice.


  • Prostate tumorigenesis in estrogen receptor [beta] inactivated, prostate targeted fibroblast growth factor 8B transgenic mice

    by Teresa Elo, Lan Yu, Eeva Valve, Sari Makela, Pirkko Harkonen

    Prostate cancer is a commonly diagnosed malignancy in Europe. Bone is one of the common metastasis sites. There is increasing evidence for estrogen involvement in the prostate tumorigenesis. ERβ knockout (BERKO) mice have been reported to have anti-proliferative, anti-inflammatory and potential anti-tumorigenic functions of ERβ. However, prostate phenotype of BERKO mice has been under debate. The potential effect of ERβ on prostate tumorgenesis was studied by crossing BERKO mice with prostated targeted fibroblast growth factor 8b (Fgf8b-Tg) mice. Fgf8b-Tg mice develop advancing stromal and epithelial changes in the prostate that slowly progress to prostatic intraepithelial neoplasia (PIN) lesions and to prostate cancer with mixed features of adenocarcinoma and sarcoma at old age. In addition, androgen receptor staining was decreased in the transformed epithelium and in the hypercellular stroma but strongly increased in the sarcoma-like lesions of Fgf8b-Tg mice. Prostate phenotypes of 1- year-old WT, Fgf8b-Tg, BERKO and Fgf8b-Tg-BERKO were analyzed. Fgf8b-Tg mice contained similar change as previously reported, including stromal aberration, PIN lesion, inflammation and cancer. The prostate of BERKO mice contained mild epithelial hypercellularity and inflammation, but not neoplastic changes. Prostate phenotype of Fgf8b-Tg-BERKO mice was mostly similar to that of Fgf8b-Tg mice. However, mucinous metaplasia was statistically significantly more frequent in the prostate of Fgf8b-Tg-BERKO mice than in the Fgf8b-Tg mice. In addition, inflammation and stromal and epithelial hypercellularity were slightly more frequent in the prostate of Fgf8b-Tg-BERKO than in the Fgf8b-Tg mice. Our results suggest that ERβ could have a role in differentiation of the prostatic epithelium and in the protection from inflammation, but do not provide evidence for a direct role of ERβ as a tumor suppressor.

  • Fibroblast Growth Factor 8b Causes Progressive Stromal and Epithelial Changes in the Epididymis and Degeneration of the Seminiferous Epithelium in the Testis of Transgenic Mice1

    by Teresa Elo, Petra Sipilä, Eeva Valve, Paula Kujala, Jorma Toppari, Matti Poutanen, Pirkko Härkönen

    Transgenic (Tg) mice expressing human fibroblast growth factor 8b (FGF8-b) under the probasin promoter (Tg [Pbsn-FGF8] L2-L5Elo; hereafter referred to as FGF8-b-Tg) were shown to produce FGF8-b at high levels in the prostate and epididymis and at lower levels in the testis. The present study examined the effects of FGF8-b expression on the epididymis and testis. In old (age, >6 mo) FGF8-b-Tg mice, epididymides were frequently enlarged, with epithelial and stromal hypercellularity progressing upon aging to epithelial dysplasia and malignant transformation of stroma. In addition, oligospermia, dilatation of the duct, and inflammation were frequently observed in the epididymides. In association with the epididymal changes, some FGF8-b-Tg mice presented a degenerative seminiferous epithelium of the testis. Consistent with this observation, infertile males were found in two FGF8-b-Tg mouse lines. Masson trichrome staining and immunohistochemical analysis of smooth muscle actin, laminin, and androgen receptor revealed that changes in the epididymal stroma closely resembled those previously found in the prostates of the FGF8-b-Tg mice. Genes previously found to be upregulated in the prostate of FGF8-b-Tg mice, such as osteopontin (Spp1) connective tissue growth factor (Ctgf), apolipoprotein D (Apod), and FGF receptor 1c (Fgfr1-c), were also upregulated in the epididymides, suggesting that similar molecular mechanisms were active in both tissues. However, unlike in the prostate, the changes in the epididymal epithelium of the FGF8-b-Tg mice did not progress into invasive carcinoma. The results suggest that prolonged and enhanced FGF signaling induces dramatic changes in the epididymis and testis that lead to infertility in a portion of the FGF8-b-Tg males.